Renal flare prediction and prognosis in lupus nephritis Hispanic patients

Lupus

Volumn 25, Issue 3, 2016, Pages 315-324

  Mejia Vilet J M ^a   Cordova Sanchez B M ^a   Arreola Guerra, J M ^a   Morales Buenrostro, L E ^a   Uribe Uribe, N O ^a   Correa Rotter, Ricardo ^a  

^a National Institute for Medica Sciences and Nutrition Salvador Zubiran   (Mexico)

Author keywords

azathioprine; cyclophosphamide; Hispanic; Lupus nephritis; mycophenolate; renal flare

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; PREDNISONE; STEROID; BIOLOGICAL MARKER; MYCOPHENOLIC ACID;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MESTIZO; MEXICAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADOLESCENT; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MEXICO; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AZATHIOPRINE; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CREATININE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; MEXICO; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959160848     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315606985     Document Type: Article

References (33)

1. Dooley MA, Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH, (eds). Dubois's lupus erythematosus, Philadelphia, PA: Lippincott Williams & Wilkins, 2007, pp. 1112-1130.
2. Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS,. Renal damage is the most important predictor of mortality within the damage index: Data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009; 48: 542-545.
3. Lenz O, Waheed AA, Baig A, Pop A, Contreras G,. Lupus nephritis: Maintenance therapy for lupus nephritis - do we now have a plan? Clin J Am Soc Nephrol 2013; 8: 162-171.
4. Morris HK, Canetta PA, Appel GB,. Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transplant 2013; 28: 1371-1376.
5. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: Long-term follow-up. Nephrol Dial Transplant 2006; 21: 1541-1548.
6. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticellli C,. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053.
7. Sidiropoulos PI, Kritikos HD, Boumpas DT,. Lupus nephritis flares. Lupus 2005; 14: 49-52.
8. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Long term follow up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995-1002.
9. Contreras G, Pardo V, Leclerq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
10. Houssiau FA, D'Cruz D, Sangle S, et al. MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: Results of a randomized trial. Ann Rheum Dis 2010; 69: 2083-2089.
11. Dooley MA, Jayne D, Ginzler EM, et al.ALMS Group,. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895.
12. Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM,. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course; data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 2010; 70: 393-394.
13. Korbet SM, Schwartz MM, Evans J, Lewis EJ,. Collaborative Study Group. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18: 244-254.
14. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006; 69: 1846-1851.
15. Austin HA III, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: Contribution of renal histologic data. Am J Med 1983; 75: 382-391.
16. Gordon C, Jayne D, Adu D, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263.
17. Rovin BH, Furie R, Latinis K, et al.LUNAR Investigator Group,. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-1226.
18. Flehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K,. Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis 2003; 62: 435-439.
19. Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61: 1502-1509.
20. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C,. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22: 2531-2539.
21. Ciruelo E, de la Cruz J, Lopez I, Gómez-Reino JJ,. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 2028-2034.
22. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Ther 2004; 50: 2559-2568.
23. Chan TM, Tse KC, Tang CS, Lai KN, Li FK,. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272.
24. Donadio JV, Holley KE, Ferguson RH, Ilstrup DM,. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151-1155.
25. Chan TM, Li FK, Tang CS, et al. For the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
26. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis; the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
27. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ,. Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53.
28. Mok CC, Ho CT, Chan DW, Lau CS, Wong RW,. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46: 1003-1013.
29. Morris HK, Canetta PA, Appel GB,. Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transplant 2013; 28: 1371-1376.
30. Tamirou F, D'Cruz D, Sangle S, et al.; and the MAINTAIN Nephritis Trial Group. Ann Rheum Dis (in press).
31. Mejía-Vilet JM, Arreola-Guerra JM, Córdova-Sánchez BM, et al. Comparison of lupus nephritis induction treatments in a hispanic population: a single-center cohort analysis. J Rheum 2015. Epub. DOI: 10.3899/jrheum.150395.
32. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264.
33. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA,. Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696.